Skip to main content

Month: August 2020

FTI Consulting Expands Global Aviation Offering

WASHINGTON, Aug. 06, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced continued investment in its Aviation offering with the launch of a dedicated global industry practice and the appointment of two Senior Managing Directors and four Managing Directors. This team will immediately enhance the firm’s depth of expertise for airlines, manufacturers, lenders, lessors, investors and other aviation-industry players, as they continue to respond to the changing environment, stabilize their businesses amid profound uncertainty and take a leading position to emerge from the downturn.Marc Bilbao and Neal Cohen join FTI Consulting as Senior Managing Directors within the Corporate Finance & Restructuring segment and Co-Leaders of the global Aviation offering. Scott Farnsworth, Joseph Kazanovski and Beau Roy have joined...

Continue reading

Intellia Therapeutics Announces Second Quarter 2020 Financial Results

Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-endExpanded Regeneron collaboration, receiving $100 million through upfront cash and equity investment and agreeing to co-develop treatments for hemophilia A and B using CRISPR-mediated targeted transgene insertion technologyOn track to submit an IND or IND-equivalent in 2021 for each of two wholly owned programs: NTLA-5001 for the treatment of acute myeloid leukemia and NTLA-2002 for the treatment of hereditary angioedemaEnded quarter with strong cash position of $436.8 millionCAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics...

Continue reading

Alico, Inc. Announces Two New Appointments to the Board of Directors

FORT MYERS, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announces the appointment of two new members to the Company’s Board of Directors (the “Board”).Joining our Board is Ms. Kate English and Mr. Adam Putnam. Ms. English will serve on the Compensation Committee and Nominating and Governance Committee. Mr. Putnam will serve on the Audit Committee and the Nominating and Governance Committee. Each will serve until the 2021 annual meeting of the Company’s shareholders or until her or his earlier death, resignation, or removal in accordance with the Amended and Restated Bylaws of the Company. This brings Alico’s total board membership to nine. Mr. Benjamin Fishman, Chairman of Alico’s board of directors, commented “We are pleased to welcome Ms. English and Mr. Putnam to our board...

Continue reading

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research license and option agreement with Sarepta for the use of the ImmTOR™ immune tolerance platform in Sarepta’s gene therapy programs in certain neuromuscular diseasesGene therapy program in MMA in collaboration with AskBio on track to enter the clinic in the first half of 2021; preliminary data expected in the second half of 2021Phase 3 clinical program of SEL-212 to commence with Sobi in Q3 2020; on track to report topline data from ongoing head-to-head COMPARE trial in Q3 2020Cash runway into the first quarter of 2023Company to host conference call today at 8:30 a.m. ETWATERTOWN, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences,...

Continue reading

Lantronix Provides Revenue Guidance for Fiscal 2020 Fourth Quarter, to Announce Full Results on September 10, 2020

IRVINE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Lantronix, Inc. (the “Company”) (Nasdaq: LTRX), a global provider of secure data access and management solutions for the industrial Internet of Things (IoT), today announced it will release financial results for its fiscal 2020 fourth quarter ended June 30, 2020, on September 10, 2020, after the close of the market.Revised Business OutlookFor the fourth quarter of fiscal 2020, Lantronix expects to report net revenues of $17.1 to $17.6 million, up 4% to 7% sequentially, and up 68% to 73% year over year. The company further expects that GAAP and non-GAAP earnings will grow sequentially from the third quarter of fiscal 2020 and reports that cash grew sequentially to $7.7 million. Due to difficulties in forecasting as a result of supply chain disruptions related to the COVID-19 pandemic,...

Continue reading

Huntington Ingalls Industries Reports Second Quarter 2020 Results, Provides COVID-19 Update and Updates 2020 Outlook

Revenues were $2.0 billion in the quarterOperating margin was 2.8%Diluted earnings per share was $1.30Cash from operations was $201 million, and free cash flow1 was $126 millionBacklog of $46.1 billionNEWPORT NEWS, Va., Aug. 06, 2020 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE:HII) reported second quarter 2020 revenues of $2.0 billion, down 7.4% from the second quarter of 2019. Operating income in the quarter was $57 million and operating margin was 2.8%, compared to $175 million and 8.0%, respectively, in the second quarter of 2019.The decreases in the quarter were primarily driven by unfavorable cumulative catch-up adjustments totaling $167 million resulting from updated cost and schedule assumptions across all programs. This includes $61 million resulting from discrete COVID-19 related delay and disruption estimates...

Continue reading

US Tier-1 Mobile Operator Awards Gilat a Multi-Million Dollar Service Contract for Cellular Backhaul

PETAH TIKVA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announces the award by a Tier-1 Mobile Network Operator (MNO) in the United States, of a multi-million-dollar service contract for cellular backhaul.The US Tier-1 MNO provides nationwide coverage with its LTE network that is extended with Gilat’s cellular backhaul solution over satellite. Gilat’s solution enables reach to remote areas and ensures high quality service and an excellent user experience. Gilat completed the LTE cellular backhaul satellite migration project according to schedule, during these challenging times imposed by the COVID-19 pandemic.“Gilat is pleased to support the ongoing needs of the Tier-1 MNO and to provide...

Continue reading

Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update

New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020Top-line generic product revenue of $1.1 million in 2Q 2020Launch of additional generic product expected in 2Q 2021NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the second quarter ended June 30, 2020 and provided clinical and regulatory updates on its programs.“The second quarter had major milestones for Sol-Gel, as we submitted our first NDA for Epsolay for the treatment of papulopustular rosacea,” commented Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “We look forward to...

Continue reading

GDS Announces Results of Annual General Meeting of Shareholders

SHANGHAI, China, Aug. 06, 2020 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings,” “GDS” or the “Company”) (NASDAQ: GDS), a leading developer and operator of high-performance data centers in China, today announced that it held its Annual General Meeting of Shareholders (“2020 AGM”) on August 6, 2020. Each of the ordinary resolutions submitted to the shareholders for approval at the 2020 AGM has been approved.Specifically, the shareholders of the Company passed ordinary resolutions approving:Re-election of Mr. Gary J. Wojtaszek as a director of the Company;Re-election of Mr. Satoshi Okada as a director of the Company;Confirmation of the appointment of KPMG Huazhen LLP as independent auditor of the Company for the fiscal year ending December 31, 2020;Amendment to Section 3(a) of the 2016 Equity Incentive Plan of the Company (the...

Continue reading

Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020

SALT LAKE CITY, Aug. 06, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Thursday, August 13, 2020.  During the call, R. Bryan Riggsbee, interim president and CEO and chief financial officer, and Scott Gleason, senior vice president of Investor Relations and Corporate Strategy, will provide an overview of Myriad’s financial performance for the fiscal fourth-quarter and provide a business update. To listen to the earnings call, interested parties in the United States may dial 1-800-381-7839 or +1-212-239-2905 for international callers.  All callers will be asked to reference reservation number 21966478.  The conference...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.